Background: The cytoskeleton is composed of microfilaments, intermediate filaments, and microtubules. Vimentin is a class-III  intermediate  filament of mesenchyme origin  (fibroblasts,  meothelium,  endothelium,  adipocytes, myoblasts, chondroblasts, osteoblasts). Vimentin is phosphorylated at Ser-55 during mitosis, among other sites, and vimentin undergoes reorganization during this time.  Vimentin expression in tumour epithelial cells has been reported as negative prognostic indicator for survival for patients with lung cancer and hepatocellular and breast carcinoma. High expression of vimentin is thought to contribute to the migratory and invasive phenotype of metastatic cells.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

Recommended Usage: Human and Mouse FFPE: 1:100 dilution. For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Al-Saad, S. et al. The prognostic impact of NF-𝛋B p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer. 2008 Nov 4; 99(9): 1476–1483.
  Bindels, S. et al. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene.
  2006;25:4975–4985.

* Conjugate tested on human and mouse FFPE tissue.